The 'Ozempic soup' recipe trend: What TikTok gets wrong
Quick answer
The video promotes a food recipe as a substitute for semaglutide (Ozempic), a GLP-1 receptor agonist approved by the FDA for weight management and type 2 diabetes. No dietary recipe replicates the receptor-binding mechanism of semaglutide, and the 'rapid weight loss' claim is not supported by evidence for any soup-based intervention. Patients seeking meaningful weight loss outcomes should be evaluated by a licensed provider to determine whether pharmacological treatment is appropriate.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @extensionesmaar1 actually say?
Honestly, the transcript here is nearly incoherent. The audio captured what appears to be a garbled or mistranscribed voiceover, leaving us with phrases like "I hope that my journey between being Formation and being completely resilient" and "the future is going to happen so I couldn't stop." None of that maps to any coherent health claim.
What we can work with is the caption and hashtags. The creator is promoting a recipe they're calling "sopita Ozempic" (little Ozempic soup), promising viewers it will help them "bajar muy rápido" (lose weight very fast). The hashtag #sopitaozemic makes the implied comparison explicit: this soup is supposed to mimic or replicate what Ozempic, the brand name for semaglutide, does in the body. That is a specific and verifiable claim worth taking seriously, even if the spoken content couldn't be transcribed reliably.
Does the science back this up?
No. There is no food, soup, or recipe that replicates the pharmacological mechanism of semaglutide. Full stop.
Semaglutide works by binding to GLP-1 receptors, slowing gastric emptying, suppressing appetite signaling in the hypothalamus, and stimulating insulin secretion in a glucose-dependent manner. These effects come from a synthetic peptide molecule that survives first-pass metabolism specifically because it's been engineered with albumin-binding fatty acid chains. You cannot get that from a bowl of soup.
The "Ozempic soup" trend, which spread widely on social media in 2023 and 2024, is typically a low-calorie vegetable broth recipe. Mendes et al. (2023, Nutrients) and other satiety research confirm that high-fiber, low-energy-density foods can support modest short-term fullness. But "supports satiety" is not the same as "mimics a GLP-1 receptor agonist." The weight loss seen with semaglutide in the STEP trials (Wilding et al., 2021, New England Journal of Medicine) averaged 14.9% body weight over 68 weeks at the 2.4mg dose. No soup produces that outcome.
What did they get wrong (or right)?
The misleading part is the framing, not necessarily the soup itself. A low-calorie vegetable soup is not a bad food choice. Dietary patterns emphasizing vegetables, fiber, and reduced caloric density are genuinely associated with weight management. Rolls et al. (2004, Obesity Research) showed that soup consumed before a meal reduced total caloric intake by about 20% in a controlled study. That is a real, modest effect.
What is wrong is calling this "sopita Ozempic" and implying it produces rapid weight loss the way a GLP-1 medication does. That framing sets false expectations. People who actually need treatment for obesity or type 2 diabetes may delay seeking medical care because they believe a recipe will do the same job. That delay has real health consequences.
The phrase "bajas muy rápido" (you lose weight very fast) is also not supported by any evidence for a soup recipe. Rapid weight loss from diet alone typically requires severe caloric restriction, which carries its own risks including muscle loss, gallstone formation, and nutrient deficiency (Tsai and Wadden, 2006, Annals of Internal Medicine).
What should you actually know?
GLP-1 receptor agonists like semaglutide and tirzepatide are prescription medications regulated by the FDA. They require a clinical evaluation, ongoing monitoring, and a prescription from a licensed provider. They are not interchangeable with food, supplements, or recipes, regardless of what a TikTok caption implies.
If you are looking for dietary changes that genuinely support weight management, the evidence points toward high-protein meals, fiber-rich vegetables, and reduced ultra-processed food intake as components of a sustainable approach. Jensen et al. (2014, Circulation) from the American Heart Association and American College of Cardiology guidelines on obesity management outline what dietary interventions can actually accomplish without medication.
If your weight is affecting your health and you want to explore whether a GLP-1 medication might be appropriate for you, that conversation starts with a licensed clinician, not a soup recipe. FormBlends connects patients with regulated telehealth providers who can do that evaluation properly.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 11 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For The 'Ozempic soup' recipe trend: What TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes a food recipe as a substitute for semaglutide (Ozempic), a GLP-1 receptor agonist approved by the FDA for weight management and type 2 diabetes.
FormBlends verdict
The video promotes a food recipe as a substitute for semaglutide (Ozempic), a GLP-1 receptor agonist approved by the FDA for weight management and type 2 diabetes. No dietary recipe replicates the receptor-binding mechanism of semaglutide, and the 'rapid weight loss' claim is not supported by evidence for any soup-based intervention. Patients seeking meaningful weight loss outcomes should be evaluated by a licensed provider to determine whether pharmacological treatment is appropriate.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes a food recipe as a substitute for semaglutide (Ozempic), a GLP-1 receptor agonist approved by the FDA for weight management and type 2 diabetes. No dietary recipe replicates the receptor-binding mechanism of semaglutide, and the 'rapid weight loss' claim is not supported by evidence for any soup-based intervention. Patients seeking meaningful weight loss outcomes should be evaluated by a licensed provider to determine whether pharmacological treatment is appropriate.
- Semaglutide (Ozempic, Wegovy) produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). No food or recipe has been shown to produce comparable results.
- Soup consumed before a meal reduced caloric intake by roughly 20% in one controlled study (Rolls et al., 2004, Obesity Research), but that is a modest meal-level effect, not a treatment for obesity.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide (Ozempic, Wegovy) produced an average 14.9% body weight reduction over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM). No food or recipe has been shown to produce comparable results.
- Soup consumed before a meal reduced caloric intake by roughly 20% in one controlled study (Rolls et al., 2004, Obesity Research), but that is a modest meal-level effect, not a treatment for obesity.
- The 'Ozempic soup' trend conflates low-calorie eating with GLP-1 receptor agonism. These are biologically unrelated mechanisms.
- Rapid weight loss through severe caloric restriction carries documented risks including gallstone formation, lean mass loss, and micronutrient deficiency (Tsai and Wadden, 2006, Annals of Internal Medicine).
- GLP-1 receptor agonists are FDA-regulated prescription medications. They require clinical evaluation and ongoing provider oversight, not a recipe substitution.
- The spoken transcript in this video was incoherent and could not be evaluated for specific medical claims. All fact-checking here is based on the caption and hashtag framing.
- If you are considering a GLP-1 medication for weight management, a licensed clinician should assess your eligibility based on BMI, comorbidities, and medical history before any treatment begins.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
extensionesmaar1 · TikTok creator
1.6K views on this video
Te urge bajar de peso esta receta bajas muy rápido #bajarpeso #receta #sopitaozemic
Sources & references
- [1]Mendes et al. (2023)
- [2]Wilding et al., 2021
- [3]Rolls et al. (2004)
- [4]Jensen et al. (2014)
- [5]Tsai and Wadden, 2006
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by extensionesmaar1, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.